Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are quite possibly the most maturely designed TPD methods. On this evaluation, we focus on equally preclinical experiments and clinical trials to offer a comprehensive summary of the protection and clinical efficiency of PROTACs and MGDs in hematologic malignancies in the last https://billv752kpu5.wikistatement.com/user